

Maria Rescigno

Female, Italian

Via Lecco 12, 20124, Milan, Italy

2 children

orcid.org/0000-0002-6464-509X[Scopus Author ID: 7005694273](#)

Researcher ID: J-9704-2012

Total h-index: 75 (Scopus)

Total n. of citations: >40.000

**EDUCATION AND TRAINING****2000-2001** Università di Milano-Bicocca, IT**1999-2001** Università di Milano, IT**1995-2000** Università di Milano, IT**1991-1994** University of Cambridge, UK**1986-1990:** Università di Milano, IT

Post-Doc in Mucosal immunology

Diploma of Specializing school in Applied Biotechnology, 50/50 Excellent

PhD in Pharmacology and Toxicology, Excellent

Visiting Scholar

Degree in Biology, 110/110 cum laude

RESEARCH AND PROFESSIONAL EXPERIENCE:

2024-present: Member of the scientific and technical committee (CTS) of AIRC

2023-present: Vice scientific director Humanitas Research Hospital

2023-present: Director Immunology programme Humanitas Research Hospital

2019-present: Vice rector and delegate for Research Humanitas University, Milan2018-present: Full Professor General Pathology Humanitas University, Milan

2018- present: Group leader Mucosal Immunology and microbiota Unit, Humanitas Research Hospital

2018-2024 Coordinator PhD programme Humanitas University

2019-present: Member and chair EMBO council

2019-present: Member of the advisory Board L'Oreal-Unesco prize for women in science

2016-present: Founder and president of Postbiotica s.r.l. a spin-off of the University of Milan

2018-present: Member of the evaluation committee SPIRIT program (Swiss National Science Foundation)

2023-present: Member of the scientific advisory board of I3S institute in Porto, Portugal

2022-present: Member of the scientific advisory board of IRB, Bellinzona, CH

2022-present: Member of the scientific advisory board of Istituto Oncologico di Bari

2019-present: Panel member ERC consolidator grant LS6

2019-2022: Member of the evaluation committee Italian Institute of Technology (IIT)

2017-2021: Member of the scientific and technical committee (CTS) of AIRC

2014-2018: Director Immunotherapy program European Institute of Oncology, Milan2001-2017: European Institute of Oncology, Milan: Director of Experimental Oncology Unit on Dendritic cell biology and Immunotherapy.2014-2017: Associate Professor, Department of Health Science, University of Milan

2013: Abilitazione Nazionale I-Fascia settori disciplinari: 06/A2 (Patologia Generale Med04); 05/F1 (Biologia Applicata, Bio13)

- 2012-2016: Chair of the scientific and technical committee of Cogentech (a facility company established at IEO)
- 2012-2017: Member of the scientific and technical committee of the IEO Biobank
- 2008-2013: Visiting Professor University of Oslo; Subject: immunology
- 2000-2001: Università degli studi di Milano-Bicocca: Dipartimento Di Biotecnologie e Bioscienze. Postdoctoral Fellow
- 1995-1999: CNR, Consiglio Nazionale delle Ricerche: PhD in Pharmacology and Toxicology in the laboratory of Dr Paola Ricciardi-Castagnoli, Prof. of Immunology , Università di Milano, Italy.
- 1991-1994: University of Cambridge, U.K Fellow in the laboratory of Dr. Richard Perham, Prof. of Biochemistry, Department of Biochemistry, University of Cambridge, UK.

Major achievements:

Maria Rescigno has been pioneering the study of the interaction between host and microbes. She has demonstrated that dendritic cells sample luminal antigens and bacteria for the establishment of oral tolerance (Nature Immunol. 2001, Nature Immunology, 2005, Immunity 2007, Immunity 2014). She has described the existence of a gut vascular barrier that controls antigen and bacteria entrance in the systemic circulation (Science 2015). This barrier can be modified by bacteria and favor tumor cell metastatization to the liver (Cancer Cell 2021). She has recently identified a new vascular barrier in the choroid plexus that controls the dialogue between the brain and the rest of the organism and that is closed down during intestinal inflammation to protect the brain. (Science 2021). She also improved protocols for cancer immunotherapy by understanding new immune-mediated mechanisms of actions of Cetuximab (2015) and of mytomicin C (Science Translational medicine, 2020), novel immune checkpoint blocker CHI3L1 (J. Immunotherapy of Cancer, 2022) and recently immunotherapy via the use of bacterial metabolites (Ferrari et al Cancer Cell, 2023).

Honors and Awards:

- 1995-99: Winner of the MURST fellowship (Borsa Ministeriale) to attend the PhD in Pharmacology and Toxicology
- 1996: Winner of the Award from the “Fondazione Adriano Buzzati Traverso”
- 1998: *1998 Cell Biology Roche Award* received in Viterbo during the XXVI Convegno Nazionale del Gruppo di cooperazione in Immunologia (GCI).
- 1999: Winner of the *Premio per le colture cellulari Mascia Brunelli*
- 2000-01: Winner of the FIRC short term fellowship to set up a collaboration with Prof. R. Steinman at Rockefeller University NY
- 2006: Elected **EMBO Young Investigator**
- 2007: Associate Editor *Mucosal Immunology*
- 2007: Awarded an **ERC starting grant** (Dendroworld)
- 2008: Nominated member of the Henry Kunkel Society.
- 2008-13: Visiting Professor University of Oslo
- 2008: Associate Editor *European Journal of Immunology, Beneficial Microbes, Immunology and Cell Biology*
- 2011: Winner of the Avon prize as the woman symbol of the city of Milan
- 2011: Elected **EMBO member**
- 2012: Awarded an **ERC Proof-of-concept grant** (7TReImHo)
- 2013: Awarded an **ERC Consolidator grant** (HomeoGUT)
- 2017: Winner of **Bioupper** with Postbiotica S.r.l.
- 2017: Winner of **Mystart BCN** (Barcelona, Spain) with Postbiotica S.r.l.

- 2022: **Honourable mention** conferred by the Belgian Embassy in Rome in collaboration with Galapagos biotech during the Biotech Bridge.
- 2022: **Premio Roma** per Economia, impresa e sociale (Rome award for economy, entrepreneurship and social activity)
- 2023: **Premio Fondazione De Sanctis for Social Health** (Salute Sociale)
- 2024: **The Pezcoller-Marina Larcher Fogazzaro-EACR Women in Cancer Research Award**

Member of the board of directors

2021-present: Fondazione Humanitas per la Ricerca

2016-present: Postbiotica s.r.l.

Collaborations:

Dr. Gerard Eberl, Institute Pasteur, Paris (France)

Dr Maria Caral Parrini, Institute Curie, Paris (France),

Prof. Iliyan Iliev, Cornell school of medicine (NY, USA),

Prof. Nicola Segata, Trento (Italy)

Prof. Alberto Bardelli, Torino (Italy)

Grant-Journal Reviewer

I am reviewer of the following *grant agencies*:

NIH, AICR, AIRC, Broad Medical Research Foundation, Wellcome Trust, Dutch Digestive Foundation, German Israeli Foundation, EMBO.

I am reviewer of the following *Journals*:

Blood, Cancer Res, Cell Host and Microbe, Eur. J Cancer, Eur. J Immunol., Gut, Immunity, J. Biol. Chem, J. Clin. Invest., J. Exp. Med., J. Leuk. Biol., Microbes and Inf., Nature, Nat. Immunol., PloS journals, Science, Trends in Immunol., Trends in Microbiol., Trends in Mol. Med.

Journal associate editor

Mucosal Immunology 2007-2016

Eur. J. Immunol. 2008-2016

Beneficial Microbes since 2008

Immunol. Cell Biol. since 2008

Journal for ImmunoTherapy of Cancer since 2012

Cell Mol Gastroenterol Hepatol. Since 2017 (board of editors)

EMBO Molecular Medicine since 2017 (board of editors)

Invitations to international meetings/seminars:

From November 2001 (the beginning of my independent career) I have been invited to give a seminar more than 300 times (either at meetings or Institutions).

Organization of meetings:

2024: IHMC, International congress on Microbiota, Rome (Organizer)
2020 – pres. MicrobiotaMi 2020 – 2022, International conference on Microbiota (Organizer)
2018 - GUT-Liver axis - EASL monothematic conference (Organizer)
2017 - Immutrain & UniVacFlu (European ITN) joint-Workshop (Organizer)
2013 – ICI Milan (International Congress of Immunology, scientific advisory board)
2011 – ICMI Paris (International Congress of Mucosal Immunology, scientific advisory board)
2010 – Cross-talk (European ITN) workshop (Organizer)
2009 – ICMI Boston (International Congress of Mucosal Immunology, scientific advisory board)
2008 – EMIG Milan (European Mucosal immunology group meeting) - organizer
2004 – Dendritic cells in Cancer Immunotherapy, workshop (sponsored by Miltenyi, Organizer)

Patents (Inventor):

PCT/EP2011/063440: **Method of antigen loading for immunotherapy**

WO2011/009848. **Therapeutic use of probiotics**

EP 13 162 326.6: **Thymic stromal lymphopoietin fragments and uses thereof**

EP n. 15194078.0: " **Method for obtaining tumor peptides and uses thereof**".

US 61/821,990: **Probiotics and methods of use**

PCT/EP2017/069681: **Postbiotic-based composition for treatment of ocular inflammation**

PCT/EP2019/052665: **"Use of a postbiotic-based composition for the treatment of skin diseases" deposited in USA, Canada, EPO**

PCT/EP2019/052669: **"Postbiotic-based composition for the modulation of immune system activation and protection of mucosal barriers" deposited in USA, Canada, EPO**

ET/151265A **Composizione a base di postbiotici per il trattamento di tumori**

WO2021013884 **CHI3L1 inhibitors and uses thereof**

WO2022008634 **Tumor-associated peptides and uses thereof**

Participation to National and International excellence groups

Partner of European Network,:

FP7 : IBDase, MetaHIT, Cross-talk, Immutrain, UniVacFlu

Horizon 2020: Arturo, T-RAFIC

Coordinator of Networks of the Italian Ministry of Health (Ricerca finalizzata)

Founder with Anna Mondino of the Milan Meets Immunology group (a group gathering all the Immunologists from Milan that meets every 1-2 times a year).

LIST of PUBLICATIONS

Total n. of publications: 232

1. Vanoni M. A., Edmondson D. E., **Rescigno M.**, Zanetti G. and Curti B.: "Mechanistic studies on *Azospirillum brasilense* Glutamate Synthase" (1991) *Biochemistry* 30, 11478-11484.
2. Vanoni M. A., Nuzzi L., **Rescigno M.**, Zanetti G. and Curti B.: "The kinetic mechanism of the reactions catalyzed by the glutamate synthase from *Azospirillum brasilense*" (1991) *Eur. J. Biochem* 202, 181-189.
3. **Rescigno M.** & Perham R. N: "Structure of the NADPH Binding Motif of Glutathione Reductase: Efficiency Determined by Evolution" (1994) *Biochemistry* 33, 5721-5727.
4. Granucci F., **Rescigno M.**, Marconi G. & P. Ricciardi-Castagnoli: "Ig-specific T cell receptor transgenic T cells are not deleted in the thymus and are functional in vivo: implications for their regulatory role during the immune response", (1996) *J. Exp. Med.*, 183, 203-213.
5. Winzler C., Rovere P., Zimmermann VS., Davoust J., **Rescigno M.**, Citterio S. & Ricciardi-Castagnoli P. Checkpoints and functional stages in DC maturation (1997) *Ad. Exp. Med. & Biol.* 417:59-64
6. Lutz MB., Rovere P., Kleijmeer MJ., Assmann CU., Oorschot VM., **Rescigno M.**, Geuze HJ., Davoust J. & Ricciardi-Castagnoli P A newly identified antigen retention compartment in the FSDC precursor dendritic cell line (1997). *Ad. Exp. Med. & Biol.* 417:167-169.
7. Bachmann M.F., Lutz M.B., Layton G.T., Harris S.J., Fehr T., **Rescigno M.** and Ricciardi-Castagnoli P. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. (1996). *Eur. J. Immunol.* 26:2595-2600.
8. WinzlerC., Rovere P., **Rescigno M.**, Granucci F., Penna G., Adorini L., Zimmermann V.S., Davoust J. and Ricciardi-Castagnoli P. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. (1997) *J. Exp. Med.* 185:317-328.
9. **Rescigno M.**, Winzler C., Delia D., Mutini C., Lutz M. and Ricciardi-Castagnoli P. Dendritic cell maturation is required for initiation of the immune response. (1997) *J. Leuk. Biology* 61:415-421.
10. Granucci F., **Rescigno M.**, Corbella P., Longhi R. and Ricciardi-Castagnoli P. Ig-specific T cells regulate the fate of the B cells during the immune response in a TCR transgenic mouse model. (1997) *Ann. N. Y. Acad. Sci.* 815:119-121.
11. Lutz M.B., Rovere P., Kleijmeer M.J., Aßmann C.U., Oorschot V.M.J., **Rescigno M.**, Trucy J., Demandolx D., Geuze H.J., Davoust J. and Ricciardi-Castagnoli P. Intracellular routes and selective retention of antigens in mildly acidic cathepsin D/Lamp-1 positive vesicles in immature dendritic cells. (1997) *J. Immunol.* 159:3707-3716
12. **Rescigno M.**, Citterio S., Théry C., Rittig M., Medaglini D., Pozzi G., Amigorena S. and Ricciardi-Castagnoli P. Bacterial-induced neo-biosynthesis, stabilization and surface expression of functional class I MHC molecules in mouse dendritic cells. (1998) *Proc. Natl Acad. Sci.* 95:5229-5234
13. Théry C., Brachet V., Regnault A., **Rescigno M.**, Ricciardi-Castagnoli P., Bonnerot C. and Amigorena S. MHC class II transport from lysosomal compartments to the cell surface is determined by stable

peptide binding, but not by the cytoplasmic domains of the α and β chains. (1998) *J Immunol.* 161:2106-2113.

14. **Rescigno M.**, Martino M., Sutherland C., Gold M.R., Ricciardi-Castagnoli P. Dendritic cell survival and maturation are regulated by different signalling pathways. (1998) *J. Exp. Med.* 188:2175-2180.
15. Rovere P, Vallinoto C, Bondanza A, Crosti MC, **Rescigno M**, Ricciardi-Castagnoli P, Rugarli C & Manfredi AA, Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function (1998) *J Immunol.*, 161:4467-71.
16. Gasperi C., **Rescigno M.**, Aggujaro D., Granucci F., Foti M., Citterio S., Matyszak M.K., Sciarpi M.T., Lanfranccone L. & Ricciardi-Castagnoli P. Retroviral gene transfer, rapid selection and maintenance of the immature phenotype in mouse dendritic cells (1999) *J. Leukoc. Biol.* 66:263-267
17. **Rescigno M.**, Granucci F., Citterio S., Foti M. & Ricciardi-Castagnoli P. Coordinated events during bacteria-induced DC maturation (1999) *Immunology Today*, 20:200-203.
18. Regnault A., Lankar D., Lacabanne V., Rodriguez A., Thery C., **Rescigno M.**, Saito T., Verbeek S., Bonnerot C., Ricciardi-Castagnoli P. & Amigorena S. Fc γ R-mediated induction of dendritic cell maturation and MHC class I-restricted antigen presentation after immune complex internalization (1999) *J. Exp. Med.*, 189:371-380.
19. **Rescigno M.**, Granucci F. and Ricciardi-Castagnoli P. Dendritic cells at the end of the millenium (1999) *Immunol Cell Biol* 77:404-10.
20. Corinti S, Medaglini D, Cavani A, **Rescigno M**, Pozzi G, Ricciardi-Castagnoli P, Girolomoni G Human dendritic cells very efficiently present a heterologous antigen expressed on the surface of recombinant gram-positive bacteria to CD4⁺ T lymphocytes. (1999) *J Immunol* 163:3029-36
21. Matyszak MK, Citterio S, **Rescigno M**, Ricciardi-Castagnoli P Differential effects of corticosteroids during different stages of dendritic cell maturation. (2000) *Eur J Immunol* 30:1233-1242
22. **Rescigno M.**, Granucci F. and Ricciardi-Castagnoli P. Molecular Events of Bacterial-Induced Maturation of Dendritic Cells (2000) *J. Clinical Immunol.* 20:161-6
23. **Rescigno M**, Piguet V, Valzasina B, Lens S, Zubler R, French L, Kindler V, Tschopp J and Ricciardi-Castagnoli P. Fas engagement induces the maturation of Dendritic Cells and the release of IL-1 β supporting an inflammatory role for FasL, (2000). *J. Exp. Med.* 4;192:1661-1668.
24. Granucci F, Di Tota FP, Raimondi G, Citterio S, **Rescigno M**, Ricciardi-Castagnoli P. Autoreactive isotype-specific T cells determine B cell frequency.(2001) *Eur J Immunol* 31:215-224
25. Hofer S, **Rescigno M**, Granucci F, Francolini M, Citterio S and Ricciardi-Castagnoli P. Differential activation of NF- κ B subunits in dendritic cells in response to Gram negative bacteria and to Lypopolysaccharide (2001). *Microb & Infect.* 3:259-265.
26. **Rescigno M.**, Urbano M., Valzasina B, Francolini M., Bonasio R., Kraehenbuhl JP, Granucci F, Ricciardi-Castagnoli P. Dendritic cells express occludin, establish junctions with gut epithelial cells and sample bacteria preserving epithelial barrier integrity. (2001). *Nat Immunol.* 2:361-367
27. **Rescigno, M.**, B. Valzasina, R. Bonasio, M. Urbano, and P. Ricciardi-Castagnoli. Dendritic cells loaded with recombinant bacteria expressing tumor antigens induce a protective tumor-specific response. (2001). *Clinical Cancer Research.*, 7:865-870

28. Peri F, Cipolla L, **Rescigno M**, La Ferla B, Nicotra F. Synthesis and Biological Evaluation of an Anticancer Vaccine Containing the C-Glycoside Analogue of the Tn Epitope. (2001) *Bioconjug Chem* 12:325-3288
29. **Rescigno M.** and P. Borrow. The host-pathogen interaction: new themes from dendritic cell biology (2001). *Cell*, 106:267-70.
30. Granucci, F. Vizzardelli, C. Pavelka, N. Feau, S. Persico, M. Virzi, E. **Rescigno, M.** Moro, G. Ricciardi-Castagnoli, P. Inducible IL-2 production by dendritic cells revealed by global gene expression analysis (2001) *Nat Immunol* 2:882-8
31. Kleijmeer, M., Ramm, G., Schuurhuis, D., Griffith, J., **Rescigno, M.**, Ricciardi-Castagnoli, P., Rudensky, A. Y., Ossendorp, F., Melief, C. J., Stoorvogel, W., Geuze, H. Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells (2001) *J Cell Biol.* 155:53-64
32. Granucci, F., Vizzardelli, C., Virzi, E., **Rescigno, M.**, Ricciardi-Castagnoli, P. Transcriptional reprogramming of dendritic cells by differentiation stimuli (2001) *Eur. J. Immunol.* 31:2539-2546
33. **Rescigno M**, Rotta G, Valzasina B and Paola Ricciardi-Castagnoli. Dendritic cells shuttle microbes across gut epithelial monolayers.(2001) *Immunobiology.* 204:572-81,.
34. Cipolla L, **Rescigno M**, Leone A, Peri F, La Ferla B, Nicotra F. Novel Tn antigen-containing neoglycopeptides: synthesis and evaluation as anti tumor vaccines. (2002) *Bioorg Med Chem.* 10:1639-46
35. **Rescigno M.**, Urbano M., Rimoldi M., Valzasina B., Rotta G., Granucci F. and Ricciardi-Castagnoli P. Toll-Like Receptor 4 is Not Required for the Full Maturation of Dendritic Cells nor for the Degradation of Gram-Negative Bacteria. (2002) *Eur. J. Immunol.* 32:2800-6
36. **Rescigno M.** Dendritic cells and the complexity of microbial infection. (2002) *Trends in Microbiol.* 10:425-431
37. Guermonprez P, Fayolle C, Rojas MJ, **Rescigno M**, Ladant D, Leclerc C. In vivo receptor-mediated delivery of a recombinant invasive bacterial toxoid to CD11c + CD8 alpha -CD11bhigh dendritic cells. (2002) *Eur J Immunol.* 32:3071-81
38. **Rescigno M.** Identification of a new mechanism for bacterial uptake at mucosal surfaces, which is mediated by dendritic cells. (2003) *Pathol Biol* 51:69-70.
39. Rotta G., Edwards EW, Sangaletti S., Bennett C., Ronzoni S., Colombo M.P., Steinman RM, Randolph G.J., and **Rescigno M.** Lipopolysaccharide or whole bacteria block the conversion of inflammatory monocytes into dendritic cells in vivo. (2003) *J Exp Med.* 198:1253-63.
40. Rimoldi M, Chieppa M, Vulcano M, Allavena P and **Rescigno M.** Intestinal epithelial cells control dendritic cells function (2004). *Ann. NY Acad. Sci.* 1029: 1-9
41. **Rescigno M**, Testori A, Parmiani G. What is new in melanoma research? Vaccines, Basic and Translational Research in 2003: report of a workshop at the Third Research Meeting on Melanoma, Milan, Italy, May 2003. (2004) *Melanoma Res.* 14:241-3.
42. B. Kelsall and **Rescigno M.** Mucosal Dendritic Cells in Immunity and Inflammation (2004) *Nat Immunol.* 5:1091-1095

43. Avogadri F, Martinoli C, Petrovska L, Chiodoni C, Transidico P, Colombo MP, Dougan G, **Rescigno M** Cancer immunotherapy based on killing of Salmonella-infected tumour cells (2005) *Cancer Res.* 65:3920-7
44. Rimoldi, M., Chieppa, M., Vulcano, M., Allavena, P., **Rescigno, M.** Dendritic cells activated by bacteria or by bacteria-stimulated epithelial cells are functionally different. (2005) *Blood.* 106(8):2818-26.
45. Rimoldi M, Chieppa M, Salucci V, Avogadri F, Sonzogni A, Sampietro GM, Nespoli A, Viale G, Allavena P, **Rescigno M.** Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells. *Nat Immunol.* 2005 May;6(5):507-14. doi: 10.1038/ni1192. Epub 2005 Apr 10. PMID: 15821737
46. Sangaletti, S., Gioiosa, L., Guiducci, C., Rotta, G., **Rescigno, M.**, Stoppacciaro, A., Chiodoni C., and Colombo MP Accelerated dendritic cell migration and contact hypersensitivity in absence of matricellular protein SPARC (2005) *J Cell Science* Aug 15:3685-94. Epub 2005 Jul 26.
47. **Rescigno M**, Chieppa M. Gut-level decisions in peace and war. (2005) *Nat Med.* 11:254-5.
48. Rimoldi M, **Rescigno M.** Uptake and presentation of orally administered antigens. (2005) *Vaccine.* 23:1793-6.
49. Lucignani G, **Rescigno M.** The role of molecular imaging in the development of dendritic cell-based cancer vaccines. (2005) *Eur J Nucl Med Mol Imaging.* 32:725-30.
50. Curigliano G, Spitaleri G, Pietri E, **Rescigno M**, de Braud F, Cardillo A, Munzone E, Rocca A, Bonizzi G, Brichard V, Orlando L, Goldhirsch A. Breast cancer vaccines: a clinical reality or fairy tale? (2005) *Ann Oncol.* 45(3):335-6.
51. Ottobriani L, Lucignani G, Clerici M, **Rescigno M.** Assessing cell trafficking by noninvasive imaging techniques: applications in experimental tumor immunology. *Q J Nucl Med Mol Imaging.* 2005 Dec;49(4):361-6.
52. **Rescigno M.** CCR6(+) dendritic cells: the gut tactical-response unit. *Immunity.* 2006 May;24(5):508-10.
53. Curigliano G, Magni E, Renne G, De Cobelli O, **Rescigno M**, Torrisi R, Spitaleri G, Pietri E, De Braud F, Goldhirsch A. Burned out" phenomenon of the testis in retroperitoneal seminoma. *Acta Oncol.* 2006;45(3):335-6.
54. Lucignani G, Ottobriani L, Martelli C, **Rescigno M**, Clerici M. Molecular imaging of cell-mediated cancer immunotherapy. (2006) *Trends Biotechnol.* 24(9):410-8
55. Chieppa M, **Rescigno M**, Huang AY, Germain RN. Dynamic imaging of dendritic cell extension into the small bowel lumen in response to epithelial cell TLR engagement (2006). *J Exp Med.* 203(13):2841-52.]
56. **Rescigno M**, Nieuwenhuis EE. The role of altered microbial signaling via mutant NODs in intestinal inflammation (2007) *Curr Opin Gastroenterol.* 23(1):21-6.
57. **Rescigno M**, Avogadri F, Curigliano G. Challenges and prospects of immunotherapy as cancer treatment. *Biochim Biophys Acta.* 2007 Sep;1776(1):108-23.
58. Curigliano G, **Rescigno M**, Goldhirsch A. Immunology and breast cancer: Therapeutic cancer vaccines. *Breast.* 2007 Dec;16 Suppl 2:S20-6.

59. He B, Xu W, Santini PA, Polydorides AD, Chiu A, Estrella J, Shan M, Chadburn A, Villanacci V, Plebani A, Knowles DM, **Rescigno M**, Cerutti A. Intestinal bacteria trigger T cell-independent immunoglobulin A(2) class switching by inducing epithelial-cell secretion of the cytokine APRIL. *Immunity*. 2007 Jun;26(6):812-26.
60. Iliev I.D., Matteoli G. and **Rescigno M**. The yin and yang of intestinal epithelial cells in controlling dendritic cell function. *J. Exp. Med.* 2007 Oct 1;204(10):2253-7.
61. Martinoli C, Chiavelli A, and **Rescigno M**. Entry route of Salmonella typhimurium directs the type of induced immune response. *Immunity*, 2007 Dec;27(6):975-84.
62. Rotta G, Matteoli G, Mazzini E, Nuciforo P, Colombo MP, **Rescigno M**. Contrasting roles of SPARC-related granuloma in bacterial containment and in the induction of anti-Salmonella typhimurium immunity. *J Exp Med*. 2008 Mar 17;205(3):657-67. Epub 2008 Mar 3.
63. Salucci V, Rimoldi M, Penati C, Sampietro GM, van Duist MM, Matteoli G, Saibeni S, Vecchi M, Ardizzone S, Porro GB, **Rescigno M**. Monocyte-derived dendritic cells from Crohn patients show differential NOD2/CARD15-dependent immune responses to bacteria. *Inflamm Bowel Dis*. 2008 Jun;14(6):812-8.
64. Gianotti L, Sargenti M, Galbiati F, Nespoli L, Brivio F, **Rescigno M**, Nespoli A. Phenotype and function of dendritic cells and T-lymphocyte polarization in the human colonic mucosa and adenocarcinoma. *Eur J Surg Oncol*. 2008 Aug;34(8):883-9.
65. Vetrano S, **Rescigno M**, Cera MR, Tognoli F, Doni A, Fantini M, Sturm A, Borroni E, Locati M, Malesci A, Dejana E, Danese S Unique role of Junctional Adhesion Molecule-A in maintaining mucosal integrity in Inflammatory Bowel Disease. *Gastroenterology*. 2008 Jul;135(1):173-84.
66. **Rescigno M**. The pathogenic role of intestinal flora in IBD and colon cancer. *Curr Drug Targets*. 2008 May;9(5):395-403.
67. **Rescigno M**, Matteoli G. Lamina propria dendritic cells: for whom the bell TOLLs? *Eur J Immunol*. 2008 Jun;38(6):1483-6.
68. Avogadri, F., Mittal, D, Saccheri, F., Sarrafiore M., Ciocca M., Larghi, P., Orecchia, R., and **Rescigno M**. Intratumoral Salmonella typhimurium induces systemic antitumor immune response that is directed by low dose radiation to treat distal disease. *Eur. J. Immunol*. 2008 Jul;38(7):1937-47.
69. Cerutti A, **Rescigno M**. The biology of intestinal immunoglobulin A responses. *Immunity*. 2008 Jun;28(6):740-50.
70. **Rescigno M**, Lopatin U, Chieppa M. Interactions among dendritic cells, macrophages, and epithelial cells in the gut: implications for immune tolerance. *Curr Opin Immunol*. 2008 Dec;20(6):669-75. Epub 2008 Oct 22.
71. Iliev ID, Mileti E, Matteoli G, Chieppa M, **Rescigno M**. Intestinal epithelial cells promote colitis-protective regulatory T-cell differentiation through dendritic cell conditioning. *Mucosal Immunol*. 2009 Jul;2(4):340-50. Epub 2009 Apr 22.
72. Maddaluno L, Verbrugge SE, Martinoli C, Matteoli G, Chiavelli A, Zeng Y, Williams ED, **Rescigno M**, Cavallaro U. The adhesion molecule L1 regulates transendothelial migration and trafficking of dendritic cells. *J Exp Med*. 2009 Mar 16;206(3):623-35. Epub 2009 Mar 9

73. Iliev ID, Spadoni I, Mileti E, Matteoli G, Sonzogni A, Sampietro GM, Foschi D, Caprioli F, Viale G, **Rescigno M**. Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells. *Gut*. 2009 Nov;58(11):1481-9.
74. **Rescigno M**, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease. *J Clin Invest*. 2009 Sep;119(9):2441-50.
75. Mileti E, Matteoli G, Iliev ID, **Rescigno M**. Comparison of the immunomodulatory properties of three probiotic strains of Lactobacilli using complex culture systems: prediction for in vivo efficacy. *PLoS One*. 2009 Sep 16;4(9):e7056.
76. **Rescigno M**, Iliev ID. Interleukin-23: linking mesenteric lymph node dendritic cells with Th1 immunity in Crohn's disease. *Gastroenterology*. 2009 Nov;137(5):1566-70. Epub 2009 Sep 27.
77. Daneman R, **Rescigno M**. The Gut Immune Barrier and the Blood-Brain Barrier: Are They So Different? *Immunity*. 2009 Nov 20;31(5):722-35.
78. **Rescigno M**. Before they were gut dendritic cells. *Immunity*. 2009 Sep 18;31(3):454-6.
79. **Rescigno M**. Functional specialization of antigen presenting cells in the gastrointestinal tract. *Curr Opin Immunol*. 2010 Feb;22(1):131-6. Epub 2010 Jan 8.
80. Murakami M, Francavilla C, Torselli I, Corada M, Maddaluno L, Sica A, Matteoli G, Iliev ID, Mantovani A, **Rescigno M**, Cavallaro U, Dejana E. Inactivation of junctional adhesion molecule-A enhances antitumoral immune response by promoting dendritic cell and T lymphocyte infiltration. *Cancer Res*. 2010 Mar 1;70(5):1759-65.
81. Bedoui S, Kupz A, Wijburg OL, Walduck AK, **Rescigno M**, Strugnell RA. Different bacterial pathogens, different strategies, yet the aim is the same: evasion of intestinal dendritic cell recognition. *J Immunol*. 2010 Mar 1;184(5):2237-42.
82. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J; MetaHIT Consortium (**Rescigno M**), Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature*. 2010 Mar 4;464(7285):59-65.
83. Oozeer R, **Rescigno M**, Ross RP, Knol J, Blaut M, Khlebnikov A, Doré J. Gut health: predictive biomarkers for preventive medicine and development of functional foods. *Br J Nutr*. 2010 May;103(10):1539-44.
84. Matteoli G, Mazzini E, Iliev ID, Mileti E, Fallarino F, Puccetti P, Chieppa M, **Rescigno M**. Gut CD103+ dendritic cells express indoleamine 2,3-dioxygenase which influences T regulatory/T effector cell balance and oral tolerance induction. *Gut*. 2010 May;59(5):595-604.
85. Mittal D, Saccheri F, Vénéreau E, Pusterla T, Bianchi ME, **Rescigno M**. TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells. *EMBO J*. 2010 Jul 7;29(13):2242-52.
86. Saccheri F, Pozzi C, Avogadri F, Barozzi S, Faretta M, Fusi P, **Rescigno M**. Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. *Sci Transl Med*. 2010 Aug 11;2(44):44ra57.

87. Barbosa T, **Rescigno M**. Host-bacteria interactions in the intestine: homeostasis to chronic inflammation. *Wiley Interdiscip Rev Syst Biol Med*. 2010 Jan-Feb;2(1):80-97.
88. **Rescigno M**. Dendritic cells in tolerance induction for the treatment of autoimmune diseases. *Eur J Immunol*. 2010 Aug;40(8):2119-23.
89. Di Sabatino A, Rovedatti L, Vetrano S, Vidali F, Biancheri P, **Rescigno M**, Danese S, Macdonald TT, Corazza GR. Involvement of CD40-CD40 Ligand in Uncomplicated and Refractory Celiac Disease. *Am J Gastroenterol*. 2011 Mar;106(3):519-27. Epub 2010 Dec 7.
90. Intestinal dendritic cells. **Rescigno M**. *Adv Immunol*. 2010;107:109-38. Review.
91. Enterotypes of the human gut microbiome. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F, Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Doré J; MetaHIT Consortium, Antolín M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariáz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M, Guedon E, Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, M'rini C, Muller J, Oozeer R, Parkhill J, Renault P, **Rescigno M**, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P. *Nature*. 2011 May 12;473(7346):174-80. Epub 2011 Apr 20.
92. Lembo-Fazio L, Nigro G, Noël G, Rossi G, Chiara F, Tsilingiri K, **Rescigno M**, Rasola A, Bernardini ML. Gadd45 α activity is the principal effector of Shigella mitochondria-dependent epithelial cell death in vitro and ex vivo. *Cell Death Dis*. 2011 Feb 24;2:e122.
93. **Rescigno M**. The intestinal epithelial barrier in the control of homeostasis and immunity. *Trends Immunol*. 2011 Jun;32
94. Swiatczak B, **Rescigno M**, Cohen IR. Systemic features of immune recognition in the gut. *Microbes Infect*. 2011 Jul 7. [Epub ahead of print]
95. **Rescigno M**. Dendritic cells in bacteria handling in the gut. *J Leukoc Biol*. 2011 Jul 19. [Epub ahead of print]
96. **Rescigno M**. Dendritic cells in oral tolerance in the gut. *Cell Microbiol*. 2011 Jul 11. [Epub ahead of print]
97. Frittoli E., Matteoli G., Palamidessi A., Mazzini E., Maddaluno L., Disanza A., Yang C., Svitkina T **Rescigno, M.**,* and Scita G*. The Signaling Adaptor Eps8 Is an Essential Actin Capping Protein for Dendritic Cell Migration. *Immunity* 2011, 23;35(3):388-99

*Co-corresponding authors

98. Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, De Palma A, Mauri P, Monegal A, **Rescigno M**, Savino B, Colombo P, Jonjic N, Pecanic S, Lazzarato L, Fruttero R, Gasco A,

Bronte V, Viola A. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. *J Exp Med*. 2011 Sep 26;208(10):1949-62

99. Swiatczak B, **Rescigno M**. How the interplay between antigen presenting cells and microbiota tunes host immune responses in the gut. *Semin Immunol*. 2011 Nov 30. [Epub ahead of print]
100. Spadoni I, Iliev ID, Rossi G, **Rescigno M**. Dendritic cells produce TSLP that limits the differentiation of Th17 cells, fosters Treg development, and protects against colitis. *Mucosal Immunol*. 2012 Jan 11. doi: 10.1038/mi.2011.64. [Epub ahead of print]
101. Tsilingiri K, Barbosa T, Penna G, Caprioli F, Sonzogni A, Viale G, **Rescigno M**. Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. *Gut*. 2012 Feb 1.
102. De Pas T, Giovannini M, **Rescigno M***, Catania C, Toffalorio F, Spitaleri G, Delmonte A, Barberis M, Spaggiari L, Solli P, Veronesi G, De Braud F. Vaccines in non-small cell lung cancer: Rationale, combination strategies and update on clinical trials. *Crit Rev Oncol Hematol*. 2012 Feb 24. [Epub ahead of print]
- Corresponding author
103. Souwer Y, Griekspoor A, de Wit J, Martinoli C, Zagato E, Janssen H, Jorritsma T, Bar-Ephraïm YE, **Rescigno M**, Neefjes J, van Ham SM. Selective infection of antigen-specific B lymphocytes by Salmonella mediates bacterial survival and systemic spreading of infection. *PLoS One*. 2012;7(11):e50667. doi: 10.1371/journal.pone.0050667. Epub 2012 Nov 29.
104. Correale C, Genua M, Vetrano S, Mazzini E, Martinoli C, Spinelli A, Arena V, Biroulet LP, Caprioli F, Passini N, Panina-Bordignon P, Repici A, Malesci A, Rutella S, **Rescigno M**, Danese S. Bacterial Sensor Triggering Receptor Expressed on Myeloid Cells-2 Regulates the Mucosal Inflammatory Response. *Gastroenterology*. 2012 Oct 26. doi:p11: S0016-5085(12)01598-3. 10.1053/j.gastro.2012.10.040. [Epub ahead of print]
105. Tsilingiri K, **Rescigno M**. Should probiotics be tested on ex vivo organ culture models? *Gut Microbes*. 2012 Sep 1;3(5). [Epub ahead of print]
106. Klaenhammer TR, Kleerebezem M, Kopp MV, **Rescigno M**. The impact of probiotics and prebiotics on the immune system. *Nat Rev Immunol*. 2012 Oct;12(10):728-34. doi: 10.1038/nri3312.
107. Tsilingiri K, Sonzogni A, Caprioli F, **Rescigno M**. A novel method for the culture and polarized stimulation of human intestinal mucosa explants. *J Vis Exp*. 2013 May 1;(75). doi: 10.3791/4368.
108. **Rescigno M**. Plasmacytoid DCs are gentle guardians of tonsillar epithelium. *Eur J Immunol*. 2013 Apr;43(5):1142-6. doi: 10.1002/eji.201343533.
109. Cavarelli M, Foglieni C, **Rescigno M**, Scarlatti G. R5 HIV-1 envelope attracts dendritic cells to cross the human intestinal epithelium and sample luminal virions via engagement of the

CCR5. *EMBO Mol Med*. 2013 May;5(5):776-94. doi: 10.1002/emmm.201202232. Epub 2013 Apr 22.

110. Massa PE, Paniccia A, Monegal A, de Marco A, **Rescigno M**. Salmonella engineered to express CD20-targeting antibodies and a drug-converting enzyme can eradicate human lymphomas. *Blood*. 2013 Jun 4. [Epub ahead of print]
111. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jørgensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clément K, Doré J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T; MetaHIT consortium, Bork P, Wang J, Ehrlich SD, Pedersen O, Guedon E, Delorme C, Layec S, Khaci G, van de Guchte M, Vandemeulebrouck G, Jamet A, Dervyn R, Sanchez N, Maguin E, Haimet F, Winogradski Y, Cultrone A, Leclerc M, Juste C, Blottière H, Pelletier E, LePaslier D, Artiguenave F, Bruls T, Weissenbach J, Turner K, Parkhill J, Antolin M, Manichanh C, Casellas F, Boruel N, Varela E, Torrejon A, Guarner F, Denariáz G, Derrien M, van Hylckama Vlieg JE, Veiga P, Oozeer R, Knol J, **Rescigno M**, Brechot C, M'Rini C, Mérieux A, Yamada T. Richness of human gut microbiome correlates with metabolic markers. *Nature*. 2013 Aug 29;500(7464):541-6. doi: 10.1038/nature12506.
112. **Rescigno M**. Mucosal immunology and bacterial handling in the intestine. *Best Pract Res Clin Gastroenterol*. 2013 Feb;27(1):17-24.
113. Zagato E, Mileti E, Massimiliano L, Fasano F, Budelli A, Penna G, **Rescigno M**. Lactobacillus paracasei CBA L74 Metabolic Products and Fermented Milk for Infant Formula Have Anti-Inflammatory Activity on Dendritic Cells In Vitro and Protective Effects against Colitis and an Enteric Pathogen In Vivo. *PLoS One*. 2014 Feb 10;9(2):e87615. doi: 10.1371/journal.pone.0087615. eCollection 2014.
114. Mazzini E, Massimiliano L, Penna G, **Rescigno M**. Oral Tolerance Can Be Established via Gap Junction Transfer of Fed Antigens from CX3CR1+ Macrophages to CD103+ Dendritic Cells. *Immunity*. 2014 Jan 21. pii: S1074-7613(14)00003-X. doi: 10.1016/j.immuni.2013.12.012. [Epub ahead of print]
115. **Rescigno M**. Dendritic cell-epithelial cell crosstalk in the gut. *Immunol Rev*. 2014 Jul;260(1):118-28. doi: 10.1111/imr.12181.
116. **Rescigno M**. Intestinal microbiota and its effects on the immune system. *Cell Microbiol*. 2014 Jul;16(7):1004-13. doi: 10.1111/cmi.12301. Epub 2014 May 1.
117. Nielsen HB, Almeida M, Juncker AS, Rasmussen S, Li J, Sunagawa S, Plichta DR, Gautier L, Pedersen AG, Le Chatelier E, Pelletier E, Bonde I, Nielsen T, Manichanh C, Arumugam M, Batto JM, Quintanilha Dos Santos MB, Blom N, Borruel N, Burgdorf KS, Boumezeur F, Casellas F, Doré J, Dworzynski P, Guarner F, Hansen T, Hildebrand F, Kaas RS, Kennedy S, Kristiansen K, Kultima JR, Léonard P, Levenez F, Lund O, Moumen B, Le Paslier D, Pons N, Pedersen O, Prifti E, Qin J, Raes J, Sørensen S, Tap J, Tims S, Ussery DW, Yamada T; **MetaHIT Consortium (Rescigno M)**, Renault P, Sicheritz-Ponten T, Bork P, Wang J, Brunak S, Ehrlich SD. Identification and assembly of genomes and genetic elements in complex

metagenomic samples without using reference genomes. *Nat Biotechnol*. 2014 Jul 6. doi: 10.1038/nbt.2939. [Epub ahead of print]

118. Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S, Arumugam M, Kultima JR, Prifti E, Nielsen T, Juncker AS, Manichanh C, Chen B, Zhang W, Levenez F, Wang J, Xu X, Xiao L, Liang S, Zhang D, Zhang Z, Chen W, Zhao H, Al-Aama JY, Edris S, Yang H, Wang J, Hansen T, Nielsen HB, Brunak S, Kristiansen K, Guarner F, Pedersen O, Doré J, Ehrlich SD; **MetaHIT Consortium (Rescigno M)**, Bork P, Wang J. An integrated catalog of reference genes in the human gut microbiome. *Nat Biotechnol*. 2014 Jul 6. doi: 10.1038/nbt.2942. [Epub ahead of print]
119. **Rescigno M**. Intestinal epithelial spheroids: new tools for studying gastrointestinal diseases. *Gut*. 2014 Sep 2. pii: gutjnl-2014-307809. doi: 10.1136/gutjnl-2014-307809.
120. **Rescigno M**. Tfr cells and IgA join forces to diversify the microbiota. *Immunity*. 2014 Jul 17;41(1):9-11. doi: 10.1016/j.immuni.2014.06.012.
121. **Rescigno M**. Dendritic cell functions: Learning from microbial evasion strategies. *Semin Immunol*. 2015 Apr 2. pii: S1044-5323(15)00020-2. doi: 10.1016/j.smim.2015.03.012. [Epub ahead of print]
122. Fornasa G, Tsilingiri K, Caprioli F, Botti F, Mapelli M, Meller S, Kislat A, Homey B, Di Sabatino A, Sonzogni A, Viale G, Diaferia G, Gori A, Longhi R, Penna G, **Rescigno M**. Dichotomy of short and long thymic stromal lymphopoietin isoforms in inflammatory disorders of the bowel and skin. *J Allergy Clin Immunol*. 2015 Aug;136(2):413-22. doi: 10.1016/j.jaci.2015.04.011. Epub 2015 May 23.
123. Biancheri P, Di Sabatino A, **Rescigno M**, Giuffrida P, Fornasa G, Tsilingiri K, Pender SL, Papadia C, Wood E, Pasini A, Ubezio C, Vanoli A, Forbes A, MacDonald TT, Corazza GR. Abnormal thymic stromal lymphopoietin expression in the duodenal mucosa of patients with coeliac disease. *Gut*. 2015 Sep 4. pii: gutjnl-2014-308876. doi: 10.1136/gutjnl-2014-308876. [Epub ahead of print]
124. Fransen F, Zagato E, Mazzini E, Fosso B, Manzari C, El Aidy S, Chiavelli A, D'Erchia AM, Sethi MK, Pabst O, Marzano M, Moretti S, Romani L, Penna G, Pesole G, **Rescigno M**. BALB/c and C57BL/6 Mice Differ in Polyreactive IgA Abundance, which Impacts the Generation of Antigen-Specific IgA and Microbiota Diversity. *Immunity*. 2015 Sep 15;43(3):527-40. doi: 10.1016/j.immuni.2015.08.011. Epub 2015 Sep 8.
125. Spadoni I, Zagato E, Bertocchi A, Paolinelli R, Hot E, Di Sabatino A, Caprioli F, Bottiglieri L, Oldani A, Viale G, Penna G, Dejana E, **Rescigno M**. A gut-vascular barrier controls the systemic dissemination of bacteria. *Science*. 2015 Nov 13;350(6262):830-4. doi: 10.1126/science.aad0135.
126. **Rescigno M**. A 'fit' microbiota to potentiate cancer immunotherapy. *Genome Med*. 2015 Dec 21;7:131. doi: 10.1186/s13073-015-0256-x.
127. Guglietta S, Chiavelli A, Zagato E, Krieg C, Gandini S, Ravenda PS, Bazolli B, Lu B, Penna G, **Rescigno M**. Coagulation induced by C3aR-dependent NETosis drives protumorigenic

neutrophils during small intestinal tumorigenesis. *Nat Commun*. 2016 Mar 21;7:11037. doi: 10.1038/ncomms11037.

128. Pozzi C, Cuomo A, Spadoni I, Magni E, Silvola A, Conte A, Sigismund S, Ravenda PS, Bonaldi T, Zampino MG, Cancelliere C, Di Fiore PP, Bardelli A, Penna G, **Rescigno M**. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death. *Nat Med*. 2016 Jun;22(6):624-31. doi: 10.1038/nm.4078. Epub 2016 May 2.
129. Guglietta S, **Rescigno M**. Hypercoagulation and complement: Connected players in tumor development and metastases. *Semin Immunol*. 2016 Dec;28(6):578-586. doi: 10.1016/j.smim.2016.10.011. Epub 2016 Nov 18. Review.
130. Zagato E, Mazzini E, **Rescigno M**. The variegated aspects of Immunoglobulin A. *Immunol Lett*. 2016 Oct;178:45-9. doi: 10.1016/j.imlet.2016.04.009.
131. Di Sabatino A, Giuffrida P, Fornasa G, Salvatore C, Vanoli A, Naviglio S, De Leo L, Pasini A, De Amici M, Alvisi C, Not T, **Rescigno M**, Corazza GR. Innate and adaptive immunity in self-reported nonceliac gluten sensitivity versus celiac disease. *Dig Liver Dis*. 2016 Jul;48(7):745-52. doi: 10.1016/j.dld.2016.03.024. Epub 2016 Apr 7.
132. Pedersen HK, Gudmundsdottir V, Nielsen HB, Hyotylainen T, Nielsen T, Jensen BA, Forslund K, Hildebrand F, Prifti E, Falony G, Le Chatelier E, Levenez F, Doré J, Mattila I, Plichta DR, Pöhö P, Hellgren LI, Arumugam M, Sunagawa S, Vieira-Silva S, Jørgensen T, Holm JB, Trošt K; MetaHIT Consortium (**Rescigno M**), Kristiansen K, Brix S, Raes J, Wang J, Hansen T, Bork P, Brunak S, Oresic M, Ehrlich SD, Pedersen O. Human gut microbes impact host serum metabolome and insulin sensitivity. *Nature*. 2016 Jul 21;535(7612):376-81. Epub 2016 Jul 13.
133. Tsilingiri K, Fornasa G, **Rescigno M**. Thymic Stromal Lymphopoietin: To Cut a Long Story Short. *Cell Mol Gastroenterol Hepatol*. 2017 Jan 17;3(2):174-182. doi: 10.1016/j.jcmgh.2017.01.005. eCollection 2017 Mar. Review.
134. **Rescigno M**. The microbiota revolution: Excitement and caution. *Eur J Immunol*. 2017 Jul 4. doi: 10.1002/eji.201646576. [Epub ahead of print] Review.
135. Spadoni L, Fornasa G, **Rescigno M**. Organ-specific protection mediated by cooperation between vascular and epithelial barriers. *Nature Reviews Immunology* 2017 Sep 4. doi: 10.1038/nri.2017.100. [Epub ahead of print] Review.
136. Leonardi I, Li X, Semon A, Li D, Doron I, Putzel G, Bar A, Prieto D, **Rescigno M**, McGovern DPB, Pla J, Iliev ID CX3CR1+ phagocytes control immunity to intestinal fungi *Science* 2018 Jan 12;359(6372):232-236. doi: 10.1126/science.aao1503.
137. Nizzoli G, Burrello C, Cribiù FM, Lovati G, Ercoli G, Botti F, Trombetta E, Porretti L, Todoerti K, Neri A, Giuffrè MR, Geginat J, Vecchi M, **Rescigno M**, Paroni M, Caprioli F, Facciotti F. Pathogenicity of in-vivo generated intestinal Th17 lymphocytes is IFN γ dependent. *J Crohns Colitis*. 2018 Apr 25. doi: 10.1093/ecco-jcc/jjy051. [Epub ahead of print]
138. Turner JR, Goldenring JR, **Rescigno M**, Wells RG. State of the Journal: CMGH's Progress, Prospects, and Impact Factor. *Cell Mol Gastroenterol Hepatol*. 2017 Dec 18;5(2):157-158. doi: 10.1016/j.jcmgh.2017.12.002. eCollection 2018. No abstract available.

139. Caprara G, Prosperini E, Piccolo V, Sigismondo G, Melacarne A, Cuomo A, Boothby M, Rescigno M, Bonaldi T, Natoli G. PARP14 Controls the Nuclear Accumulation of a Subset of Type I IFN-Inducible Proteins. *J Immunol*. 2018 Apr 1;200(7):2439-2454. doi: 10.4049/jimmunol.1701117. Epub 2018 Mar 2.
140. Turner JR, Goldenring JR, **Rescigno M**, Wells RG. State of the Journal: CMGH's Progress, Prospects, and Impact Factor. *Gastroenterology*. 2018 Feb;154(3):460-461. doi: 10.1053/j.gastro.2018.01.008. No abstract available.
141. Guglietta S, **Rescigno M**. Gone with the Antibody. *Immunity*. 2018 Sep 18;49(3):386-388. doi: 10.1016/j.immuni.2018.09.003.
142. Burrello C, Garavaglia F, Cribiù FM, Ercoli G, Lopez G, Troisi J, Colucci A, Guglietta S, Carloni S, Guglielmetti S, Taverniti V, Nizzoli G, Bosari S, Caprioli F, **Rescigno M**, Facciotti F. Therapeutic faecal microbiota transplantation controls intestinal inflammation through IL10 secretion by immune cells. *Nat Commun*. 2018 Dec 5;9(1):5184. doi: 10.1038/s41467-018-07359-8.
143. Mosca F, Gianni ML, **Rescigno M**. Can Postbiotics Represent a New Strategy for NEC? *Adv Exp Med Biol*. 2019;1125:37-45. doi: 10.1007/5584_2018_314. Review.
144. Burrello C, Pellegrino G, Giuffrè MR, Lovati G, Magagna I, Bertocchi A, Cribiù FM, Boggio F, Botti F, Trombetta E, Porretti L, Di Sabatino A, Vecchi M, **Rescigno M**, Caprioli F, Facciotti F. Mucosa-associated microbiota drives pathogenic functions in IBD-derived intestinal iNKT cells. *Life Sci Alliance*. 2019 Feb 13;2(1). pii: e201800229. doi: 10.26508/lsa.201800229.
145. Verduci E, Banderali G, Montanari C, Berni Canani R, Cimmino Caserta L, Corsello G, Mosca F, Piazzolla R, **Rescigno M**, Terracciano L, Troiano E, Crosa M, Maffei C, Francavilla R. Childhood Dietary Intake in Italy: The Epidemiological "MY FOOD DIARY" Survey. *Nutrients*. 2019 May 21;11(5). pii: E1129. doi: 10.3390/nu11051129.
146. Thomas AM, Manghi P, Asnicar F, Pasolli E, Armanini F, Zolfo M, Beghini F, Manara S, Karcher N, Pozzi C, Gandini S, Serrano D, Tarallo S, Francavilla A, Gallo G, Trompetto M, Ferrero G, Mizutani S, Shiroma H, Shiba S, Shibata T, Yachida S, Yamada T, Wirbel J, Schrotz-King P, Ulrich CM, Brenner H, Arumugam M, Bork P, Zeller G, Cordero F, Dias-Neto E, Setubal JC, Tett A, Pardini B, **Rescigno M**, Waldron L, Naccarati A, Segata N. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. *Nat Med*. 2019 Apr;25(4):667-678. doi: 10.1038/s41591-019-0405-7. Epub 2019 Apr 1.
147. Sorribas M, Jakob MO, Yilmaz B, Li H, Stutz D, Noser Y, de Gottardi A, Moghadamrad S, Hassan M, Albillos A, Francés R, Juanola O, Spadoni I, **Rescigno M**, Wiest R. FXR-modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. *J Hepatol*. 2019 Jul 8. pii: S0168-8278(19)30389-7. doi: 10.1016/j.jhep.2019.06.017
148. Mouries J, Brescia P, Silvestri A, Spadoni I, Sorribas M, Wiest R, Mileti E, Galbiati M, Invernizzi P, Adorini L, Penna G, **Rescigno M**. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. *J Hepatol*. 2019 Aug 13. pii: S0168-8278(19)30471-4. doi: 10.1016/j.jhep.2019.08.005.
149. Albillos A, Gottardi A, **Rescigno M**. The gut-liver axis in liver disease: pathophysiological basis for therapy. *J Hepatol*. 2019
150. Mancini N, Peri F, **Rescigno M**, Zanoni I. Microbiome studies in the medical sciences and the need for closer multidisciplinary interplay. *Sci Signal*. 2020 Feb 4;13(617). pii: eaba9911. doi: 10.1126/scisignal.aba9911. Review.

151. Zagato E, Pozzi C, Bertocchi A, Schioppa T, Saccheri F, Guglietta S, Fosso B, Melocchi L, Nizzoli G, Troisi J, Marzano M, Oresta B, Spadoni I, Atarashi K, Carloni S, Arioli S, Fornasa G, Asnicar F, Segata N, Guglielmetti S, Honda K, Pesole G, Vermi W, Penna G, **Rescigno M**. Endogenous murine microbiota member Faecalibaculum rodentium and its human homologue protect from intestinal tumour growth. *Nat Microbiol*. 2020 Jan 27. doi: 10.1038/s41564-019-0649-5. [Epub ahead of print]
152. Mancini N, Peri F, **Rescigno M**, Zanoni I Microbiome studies in the medical sciences and the need for closer multidisciplinary interplay. *Sci Signal*. 2020 Feb 4;13(617):eaba9911. doi: 10.1126/scisignal.aba9911.PMID: 32019901 Review.
153. Martini E, Giugliano S, **Rescigno M**, Kallikourdis M. Regulatory T Cells Beyond Autoimmunity: From Pregnancy to Cancer and Cardiovascular Disease. *Front Immunol*. 2020 Mar 31;11:509. doi: 10.3389/fimmu.2020.00509. eCollection 2020.PMID: 32296427
154. Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaip US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, **Rescigno M**, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. J Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. *Immunother Cancer*. 2020 Mar;8(1):e000337. doi: 10.1136/jitc-2019-000337.PMID: 32209603
155. Roggero P, Liotto N, Pozzi C, Braga D, Troisi J, Menis C, Gianni ML, Berni Canani R, Paparo L, Nocerino R, Budelli A, Mosca F, **Rescigno M**. Analysis of immune, microbiota and metabolome maturation in infants in a clinical trial of Lactobacillus paracasei CBA L74-fermented formula. *Nat Commun*. 2020 Jun 1;11(1):2703. doi: 10.1038/s41467-020-16582-1.PMID: 32483147
156. **Rescigno M**. The "iron will" of the gut. *Science*. 2020 Apr 10;368(6487):129-130. doi: 10.1126/science.abb2915.PMID: 32273453
157. Oresta B, Braga D, Lazzeri, M., Frego, N., Saita, A., Faccani, C., Fasulo, V., Colombo, P., Guazzoni, G., Hurle, R. **Rescigno, M**. Dysbiosis of the urinary microbiome associated with bladder cancer in males. *J. Urol*. *J Urol*. 2021 Jan;205(1):86-93. doi: 10.1097/JU.0000000000001336. Epub 2020 Aug 28.PMID: 32856979
158. Oresta B, Pozzi, C., Braga D, Hurle, R, Lazzeri, M., Colombo, P., Frego, N., Erreni, M., N., Faccani, C., Elefante, G., Barcella, M., Guazzoni, G., **Rescigno, M**. Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer. *Science Transl Med*. *Sci Transl Med*. 2021 Jan 6;13(575):eaba6110. doi: 10.1126/scitranslmed.aba6110.PMID: 33408185
159. Mazzarella L, Giugliano S, D'Amico P, Belli C, Duso BA, **Rescigno M**, Curigliano G. Evidence for interleukin 17 involvement in severe immune-related neuroendocrine toxicity. *Eur J Cancer*. 2020 Nov 10;141:218-224. doi: 10.1016/j.ejca.2020.10.006. Online ahead of print.PMID: 33186857
160. Rouland M, Beaudoin L, Rouxel O, Bertrand L, Cagninacci L, Saffarian A, Pedron T, Gueddouri D, Guilmeau S, Burnol AF, Rachdi L, Tazi A, Mouriès J, **Rescigno M**, Vergnolle N, Sansonetti P, Christine Rogner U, Lehuen A. Gut mucosa alterations and loss of segmented filamentous bacteria in type 1 diabetes are associated with inflammation rather than hyperglycaemia. *Gut*. 2021 Feb 16;gutjnl-2020-323664. doi: 10.1136/gutjnl-2020-323664. Online ahead of print. PMID: 33593807

161. Serrano D, Pozzi C, Guglietta S, Fosso B, Suppa M, Gnagnarella P, Corso F, Bellerba F, Macis D, Aristarco V, Manghi P, Segata N, Trovato C, Zampino MG, Marzano M, Bonanni B, **Rescigno M**, Gandini S. Microbiome as Mediator of Diet on Colorectal Cancer Risk: The Role of Vitamin D, Markers of Inflammation and Adipokines. *Nutrients*. 2021 Jan 25;13(2):363. doi: 10.3390/nu13020363.PMID: 33504116
162. Zago M, Massimiliano L, Bonvini B, Penna G, Giraffa G, **Rescigno M**. Functional characterization and immunomodulatory properties of Lactobacillus helveticus strains isolated from Italian hard cheeses. *PLoS One*. 2021 Jan 25;16(1):e0245903. doi: 10.1371/journal.pone.0245903. eCollection 2021. PMID: 33493208 .
163. van Beek JJP, **Rescigno M**, Lugli E. A fresh look at the T helper subset dogma. *Nat Immunol*. 2021 Feb;22(2):104-105. doi: 10.1038/s41590-020-00858-1. PMID: 33462455 .
164. Bertocchi, A. Carloni, S. Ravenda, PS, Bertalot, G. Spadoni, I, Lo Cascio, A., Gandini, S. Lizier, M., Braga, D., Asnicar, F., Segata, N., Klaver, C., Brescia, P., Rossi, E., Anselmo, A., Guglietta, S., Maroli, A., Spaggiari, P., Tarazona, N., Cervantes, A., Marsoni, S., Lazzari, L., Jodice, MG, Luise, C., Erreni, M., Pece, S., and **Rescigno, M.** Gut Vascular Barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver. *Cancer Cell*, 2021, 10;39(5):708-724.e11. doi: 10.1016/j.ccell.2021.03.004.
165. Sandri MT, Azzolini E, Torri V, Carloni S, Pozzi C, Salvatici M, Tedeschi M, Castoldi M, Mantovani A, **Rescigno M**. SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy. *Sci Rep*. 2021 Jun 10;11(1):12312. Doi : 10.1038/s41598-021-91773-4.PMID: 34112899
166. Gil-Gómez A, Brescia P, **Rescigno M**, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. *Semin Liver Dis*. 2021 May;41(2):191-205. doi: 10.1055/s-0041-1723752. Epub 2021 Mar 8.PMID: 34107545
167. Frieman M, Harris AD, Herati RS, Krammer F, Mantovani A, **Rescigno M**, Sajadi MM, Simon V. SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. *EBioMedicine*. 2021 Jun;68:103401. doi: 10.1016/j.ebiom.2021.103401.
168. Levi R, Azzolini E, Pozzi C, Ubaldi L, Lagioia M, Mantovani A, **Rescigno M**. One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19. *J Clin Invest*. 2021 Jun 15;131(12):e149154. doi: 10.1172/JCI149154. PMID: 33956667
169. Aragona P, Baudouin C, Benitez Del Castillo JM, Messmer E, Barabino S, Merayo-Llodes J, Brignole-Baudouin F, Inferrera L, Rolando M, Mencucci R, **Rescigno M**, Bonini S, Labetoulle M. The ocular microbiome and microbiota and their effects on ocular surface pathophysiology and disorders. *Surv Ophthalmol*. 2021 Apr 2:S0039-6257(21)00083-7. doi: 10.1016/j.survophthal.2021.03.010.
170. **Rescigno M**. Unraveling the long-term effect of influenza vaccines. *Cell*. 2021 Jul 22;184(15):3845-3847. doi: 10.1016/j.cell.2021.06.026.PMID: 34297927
171. Melacarne A, Ferrari V, Tiraboschi L, Mishto M, Liepe J, Aralla M, Marconato L, Lizier M, Pozzi C, Zeira O, Penna G, **Rescigno M**. Identification of a class of non-conventional ER-stress-response-derived immunogenic peptides. *Cell Rep*. 2021 Jul 6;36(1):109312. doi: 10.1016/j.celrep.2021.109312.PMID: 34233181 Free PMC article.
172. Brescia P, **Rescigno M**. The gut vascular barrier: a new player in the gut-liver-brain axis. *Trends Mol Med*. 2021 Jul 3:S1471-4914(21)00154-4. doi: 10.1016/j.molmed.2021.06.007. Online ahead of print.PMID: 34229973 Review.

173. Sandri MT, Azzolini E, Torri V, Carloni S, Pozzi C, Salvatici M, Tedeschi M, Castoldi M, Mantovani A, **Rescigno M**. SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy. *Sci Rep*. 2021 Jun 10;11(1):12312. doi: 10.1038/s41598-021-91773-4.PMID: 34112899 Free PMC article. Clinical Trial.
174. Gil-Gómez A, Brescia P, **Rescigno M**, Romero-Gómez M. Gut-Liver Axis in Nonalcoholic Fatty Liver Disease: the Impact of the Metagenome, End Products, and the Epithelial and Vascular Barriers. *Semin Liver Dis*. 2021 May;41(2):191-205. doi: 10.1055/s-0041-1723752. Epub 2021 Mar 8.PMID: 34107545
175. **Rescigno M**. Unraveling the long-term effect of influenza vaccines. *Cell*. 2021 Jul 22;184(15):3845-3847.
176. Pernigoni N, Zagato E, Calcinotto A, Troiani M, Mestre RP, Cali B, Attanasio G, Troisi J, Minini M, Mosole S, Revandkar A, Pasquini E, Elia AR, Bossi D, Rinaldi A, Rescigno P, Flohr P, Hunt J, Neeb A, Buroni L, Guo C, Welte J, Ferrari M, Grioni M, Gauthier J, Gharaibeh RZ, Palmisano A, Lucchini GM, D'Antonio E, Merler S, Bolis M, Grassi F, Esposito A, Bellone M, Briganti A, **Rescigno M**, Theurillat JP, Jobin C, Gillesen S, de Bono J, Alimonti A. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. *Science*. 2021 Oct 8;374(6564):216-224
177. Aguilar-Toalá JE, Arioli S, Behare P, Belzer C, Berni Canani R, Chatel JM, D'Auria E, de Freitas MQ, Elinav E, Esmerino EA, García HS, da Cruz AG, González-Córdova AF, Guglielmetti S, de Toledo Guimarães J, Hernández-Mendoza A, Langella P, Liceaga AM, Magnani M, Martin R, Mohamad Lal MT, Mora D, Moradi M, Morelli L, Mosca F, Nazzaro F, Pimentel TC, Ran C, Ranadheera CS, **Rescigno M**, Salas A, Sant'Ana AS, Sivieri K, Sokol H, Taverniti V, Vallejo-Cordoba B, Zelenka J, Zhou Z. Postbiotics - when simplification fails to clarify. *Nat Rev Gastroenterol Hepatol*. 2021 Nov;18(11):825-826.
178. Madaghiele M, Demitri C, Surano I, Silvestri A, Vitale M, Panteca E, Zohar Y, **Rescigno M**, Sannino A. Biomimetic cellulose-based superabsorbent hydrogels for treating obesity. *Sci Rep*. **2021** Nov 1;11(1):21394. doi: 10.1038/s41598-021-00884-5.
179. Pozzi C, Levi R, Braga D, Carli F, Darwich A, Spadoni I, Oresta B, Dioguardi CC, Peano C, Ubaldi L, Angelotti G, Bottazzi B, Garlanda C, Desai A, Voza A, Azzolini E, Cecconi M; ICH COVID-19 Task-force, Mantovani A, Penna G, Barbieri R, Politi LS, **Rescigno M**. A 'Multiomic' Approach of Saliva Metabolomics, Microbiota, and Serum Biomarkers to Assess the Need of Hospitalization in Coronavirus Disease 2019. *Gastro Hep Adv*. 2022;1(2):194-209. doi: 10.1016/j.gastha.2021.12.006. Epub 2022 Feb 7.PMID: 35174369
180. Azzolini E, Pozzi C, Germagnoli L, Oresta B, Carriglio N, Calleri M, Selmi C, De Santis M, Finazzi S, Carlo-Stella C, Bertuzzi A, Motta F, Ceribelli A, Mantovani A, Bonelli F, **Rescigno M**. mRNA COVID-19 vaccine booster fosters B- and T-cell responses in immunocompromised patients. *Life Sci Alliance*. 2022 Feb 15;5(6):e202201381. doi: 10.26508/lsa.202201381. Print 2022 Jun. PMID: 35169017
181. Levi R, Ubaldi L, Pozzi C, Angelotti G, Sandri MT, Azzolini E, Salvatici M, Savevski V, Mantovani A, **Rescigno M**. The antibody response to SARS-CoV-2 infection persists over at least 8 months in symptomatic patients. *Commun Med* (London). 2021;1(1):32. doi: 10.1038/s43856-021-00032-0. Epub 2021 Sep 17. PMID: 35072166
182. Carloni, S., Bertocchi, A., Mancinelli, S., Bellini, M., Erreni, M., Borreca, A., Braga, D., Giugliano, S., Mozzarelli, A.M., Manganaro, D., Perez Fernandez, D., Colombo, F., Di Sabatino, A., Pasini, D.,

Penna, G., Matteoli, M., Lodato, S., **Rescigno, M.** Identification of a Choroid Plexus Vascular Barrier Closing during Intestinal Inflammation *Science* 2021 Oct 22;374(6566):439-448.

183. Darwich A, Silvestri A, Benmebarek MR, Mouriès J, Cadilha B, Melacarne A, Morelli L, Supino D, Taleb A, Obeck H, Sustmann C, Losurdo A, Masci G, Curigliano G, Kobold S, Penna G, **Rescigno M.** Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1. *J Immunother Cancer*. 2021 Nov;9(11):e003224. doi: 10.1136/jitc-2021-003224.
184. Burrello C, Strati F, Lattanzi G, Diaz-Basabe A, Mileti E, Giuffrè MR, Lopez G, Cribiù FM, Trombetta E, Kallikourdis M, Cremonesi M, Conforti F, Botti F, Porretti L, **Rescigno M**, Vecchi M, Fantini MC, Caprioli F, Facciotti F IL10 secretion endows intestinal human iNKT cells with regulatory functions towards pathogenic T lymphocytes. *J Crohns Colitis*. 2022 Mar 31;jjac049. doi: 10.1093/ecco-jcc/jjac049. Online ahead of print.PMID: 35358301
185. Azzolini E, Canziani LM, Voza A, Desai A, Pepys J, De Santis M, Ceribelli A, Pozzi C, Turato M, Badalamenti S, Germagnoli L, Mantovani A, **Rescigno M**, Selmi C. Short-Term Adverse Events and Antibody Response to the BNT162b2 SARS-CoV-2 Vaccine in 4156 Health Care Professionals. *Vaccines* (Basel). 2022 Mar 13;10(3):439. doi: 10.3390/vaccines10030439.PMID: 35335071
186. Marconato L, Melacarne A, Aralla M, Sabattini S, Tiraboschi L, Ferrari V, Zeira O, Balboni A, Faroni E, Guerra D, Pisoni L, Ghezzi E, Pettinari L, **Rescigno M.** A Target Animal Effectiveness Study on Adjuvant Peptide-Based Vaccination in Dogs with Non-Metastatic Appendicular Osteosarcoma Undergoing Amputation and Chemotherapy. *Cancers* (Basel). 2022 Mar 6;14(5):1347. doi: 10.3390/cancers14051347.PMID: 35267655
187. Darwich A, Pozzi C, Fornasa G, Lizier M, Azzolini E, Spadoni I, Carli F, Voza A, Desai A, Ferrero C, Germagnoli L; ICH COVID-19 Task-force, Mantovani A, **Rescigno M.** BNT162b2 vaccine induces antibody release in saliva: a possible role for mucosal viral protection? *EMBO Mol Med*. 2022 May 9;14(5):e15326. doi: 10.15252/emmm.202115326. Epub 2022 Apr 19.PMID: 35393790
188. Caldas C, **Rescigno M**, Turajlic S, Madabhushi A, Zhang Z, Lito P, Brown CE, Pantel K, Haanen J, Duma N. With one eye on the future. *Cancer Cell*. 2022 Mar 14;40(3):221-225. doi: 10.1016/j.ccell.2022.02.019.PMID: 35290781
189. Corradini P, Agrati C, Apolone G, Mantovani A, Giannarelli D, Marasco V, Bordoni V, Sacchi A, Matusali G, Salvarani C, Zinzani PL, Mantegazza R, Tagliavini F, Lupo-Stanghellini MT, Ciceri F, Damian S, Uccelli A, Fenoglio D, Silvestris N, Baldanti F, Piaggio G, Ciliberto G, Morrone A, Locatelli F, Sinno V, Rescigno M*, Costantini M*; Humoral and T-cell immune response after three doses of mRNA SARS-CoV-2 vaccines in fragile patients: the Italian VAX4FRAIL study. *Clin Infect Dis*. 2022 May 24;ciac404. doi: 10.1093/cid/ciac404. Online ahead of print.PMID: 35607769
* Co-last authors
190. Romero-Ibarguengoitia ME, González-Cantú A, Pozzi C, Levi R, Mollura M, Sarti R, Sanz-Sánchez MÁ, Rivera-Salinas D, Hernández-Ruiz YG, Armendariz-Vázquez AG, Del Rio-Parra GF, Barco-Flores IA, González-Facio R, Azzolini E, Barbieri R, de Azevedo Dias AR, Henriques Guimarães Júnior M, Bastos-Borges A, Acciardi C, Paez-Bo G, Teixeira MM, **Rescigno M.** Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries. *Front Immunol*. 2022 Jul 28;13:894277. doi: 10.3389/fimmu.2022.894277.
191. Lyden D, Ghajar CM, Correia AL, Aguirre-Ghiso JA, Cai S, **Rescigno M**, Zhang P, Hu G, Fendt SM, Boire A, Weichselbaum RR, Katipally RR. Metastasis. *Cancer Cell*. 2022 Aug 8;40(8):787-791. doi: 10.1016/j.ccell.2022.07.010.PMID: 35944497

192. Lenti MV, Facciotti F, Miceli E, Vanoli A, Fornasa G, Lahner E, Spadoni I, Giuffrida P, Arpa G, Pasini A, Rovedatti L, Caprioli F, Travelli C, Lattanzi G, Conti L, Klersy C, Vecchi M, Paulli M, Annibale B, Corazza GR, **Rescigno M**, Di Sabatino A. Mucosal Overexpression of Thymic Stromal Lymphopoietin and Proinflammatory Cytokines in Patients With Autoimmune Atrophic Gastritis. *Clin Transl Gastroenterol.* 2022 Jul 1;13(7):e00510. doi: 10.14309/ctg.0000000000000510. Epub 2022 Jun 13. PMID: 35905420
193. Carloni S, **Rescigno M**. Unveiling the gut-brain axis: structural and functional analogies between the gut and the choroid plexus vascular and immune barriers. *Semin Immunopathol.* 2022 Jul 21:1-14. doi: 10.1007/s00281-022-00955-3. Online ahead of print. PMID: 35861857 .
194. Pietrasanta C, Darwich A, Ronchi A, Crippa B, Spada E, Mosca F, Pagni L, **Rescigno M** .Humoral response to anti-SARS-CoV-2 vaccine in breastfeeding mothers and mother-to-infant antibody transfer through breast milk. *NPJ Vaccines.* 2022 Jun 23;7(1):63. doi: 10.1038/s41541-022-00499-5.
195. Mollura M, Sarti R, Levi R, Pozzi C, Azzolini E, Politi LS, Mantovani A, Barbieri R, **Rescigno M**. Antibody Titer Correlates with Omicron Infection in Vaccinated Healthcare Workers. *Viruses.* 2022 Nov 23;14(12):2605. doi: 10.3390/v14122605. PMID: 36560609
196. Bellerba F, Serrano D, Harriet J, Pozzi C, Segata N, NabiNejad A, Piperni E, Gnagnarella P, Macis D, Aristarco V, Accornero CA, Manghi P, Gonzaga AG, Biffi R, Bottiglieri L, Trovato C, Zampino MG, Corso F, Bellocchio R, Raimondi S, **Rescigno M**, Gandini S. Colorectal cancer, Vitamin D and microbiota: A double-blind Phase II randomized trial (ColoViD) in colorectal cancer patients. *Neoplasia.* 2022 Oct 21;34:100842. doi: 10.1016/j.neo.2022.100842. Online ahead of print.
197. Azzolini, ED,1 Levi, R. Sarti, R., Pozzi, C. Mollura, M. Mantovani, A., and **Rescigno, M**; Association Between BNT162b2 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers *JAMA.* Published online July 1, 2022. doi:10.1001/jama.2022.11691
198. Pugliese N, Alfarone L, Arcari I, Giugliano S, Parigi TL, **Rescigno M**, Lleo A, Aghemo A. Clinical features and management issues of NAFLD-related HCC: what we know so far. *Expert Rev Gastroenterol Hepatol.* 2023 Jan;17(1):31-43. doi: 10.1080/17474124.2023.2162503. Epub 2022 Dec 28. PMID: 36576057
199. **Rescigno M**. Training the microbiota to increase immune checkpoint blockade and to reduce toxicity. *Eur J Immunol.* 2023 Feb 6:e2250183. doi: 10.1002/eji.202250183. Online ahead of print. PMID: 36747375 Review.
200. Mantovani A, **Rescigno M**, Forni G, Tognon F, Putoto G, Ichtho J, Lochoro P. COVID-19 vaccines and a perspective on Africa. *Trends Immunol.* 2023 Jan 11:S1471-4906(23)00005-4. doi: 10.1016/j.it.2023.01.005. Online ahead of print.
201. Algieri F, Tanaskovic N, Rincon CC, Notario E, Braga D, Pesole G, Rusconi R, Penna G, **Rescigno M**. *Lactobacillus paracasei* CNCM I-5220-derived postbiotic protects from the leaky-gut. *Front Microbiol.* 2023 Mar 20;14:1157164. doi: 10.3389/fmicb.2023.1157164.
202. **Rescigno M**. Microbiota in Reflux Esophagitis and Peptic Ulcer Disease. *Surg Infect* (Larchmt). 2023 Apr;24(3):245-249. doi: 10.1089/sur.2023.021. PMID: 37010961
203. Azzolini E, Mollura M, Pozzi C, Ubaldi L, Mantovani A, Selmi C, Barbieri R, **Rescigno M**. Adverse Events to Comirnaty Vaccine Are Linked to Sex, Age and BMI: Should We Consider Reducing the Dose for Females? *Vaccines* (Basel). 2023 Feb 22;11(3):505. doi: 10.3390/vaccines11030505. PMID: 36992089

204. Pozzi C, Azzolini E, **Rescigno M.** Analyzing the diffusion and duration of antibodies to SARS-CoV-2 during the natural infection and comparison with vaccination. *Eur Phys J Plus.* 2023;138(2):140. doi: 10.1140/epjp/s13360-023-03732-9. Epub 2023 Feb 9. PMID: 36785809
205. **Rescigno M**, Agrati C, Salvarani C, Giannarelli D, Costantini M, Mantovani A, Massafra R, Zinzani PL, Morrone A, Notari S, Matusali G, Pinter GL, Uccelli A, Ciliberto G, Baldanti F, Locatelli F, Silvestris N, Sinno V, Turola E, Lupo-Stanghellini MT, Apolone G; VAX4FRAIL study Group. Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters. *Front Immunol.* 2023 Jan 27;14:1104124. doi: 10.3389/fimmu.2023.1104124.
206. **Rescigno M.** Training the microbiota to increase immune checkpoint blockade and to reduce toxicity. *Eur J Immunol.* 2023 Feb 6:e2250183. doi: 10.1002/eji.202250183. Online ahead of print. PMID: 36747375
207. Romero-Ibarguengoitia ME, Rivera-Salinas D, Sarti R, Levi R, Mollura M, Garza-Silva A, Rivera-Cavazos A, Hernández-Ruiz YG, Barco-Flores IA, González-Cantú A, Sanz-Sánchez MÁ, Guimarães Júnior MH, Pozzi C, Barbieri R, Morales-Rodriguez DP, Texeira MM, **Rescigno M.** Efficacy of Six Different SARS-CoV-2 Vaccines during a Six-Month Follow-Up and Five COVID-19 Waves in Brazil and Mexico. *Vaccines (Basel).* 2023 Apr 14;11(4):842. doi: 10.3390/vaccines11040842. PMID: 37112754
208. Algieri F, Tanaskovic N, Rincon CC, Notario E, Braga D, Pesole G, Rusconi R, Penna G, **Rescigno M.** Lactobacillus paracasei CNCM I-5220-derived postbiotic protects from the leaky-gut. *Front Microbiol.* 2023 Mar 20;14:1157164. doi: 10.3389/fmicb.2023.1157164. eCollection 2023. PMID: 37020718
209. **Rescigno M.** Microbiota in Reflux Esophagitis and Peptic Ulcer Disease. *Surg Infect (Larchmt).* 2023 Apr;24(3):245-249. doi: 10.1089/sur.2023.021. PMID: 37010961
210. Azzolini E, Mollura M, Pozzi C, Ubaldi L, Mantovani A, Selmi C, Barbieri R, **Rescigno M.** Adverse Events to Comirnaty Vaccine Are Linked to Sex, Age and BMI: Should We Consider Reducing the Dose for Females? *Vaccines (Basel).* 2023 Feb 22;11(3):505. doi: 10.3390/vaccines11030505. PMID: 36992089
211. Pozzi C, Azzolini E, **Rescigno M.** Analyzing the diffusion and duration of antibodies to SARS-CoV-2 during the natural infection and comparison with vaccination. *Eur Phys J Plus.* 2023;138(2):140. doi: 10.1140/epjp/s13360-023-03732-9. Epub 2023 Feb 9. PMID: 36785809
212. Ferrari V, **Rescigno M.** The intratumoral microbiota: friend or foe? *Trends Cancer.* 2023 Jun;9(6):472-479. doi: 10.1016/j.trecan.2023.03.005. Epub 2023 Apr 13. PMID: 37061408 Review.
213. Carloni S, **Rescigno M.** The gut-brain vascular axis in neuroinflammation. *Semin Immunol.* 2023 Sep;69:101802. doi: 10.1016/j.smim.2023.101802. Epub 2023 Jul 7.
214. Silvestri, A. Gil-Gomez, A., Vitale, M., Braga, D., Demitri, C., Brescia, P., Madaghiele, M., Spadoni, I, Jones, B., Fornasa, G, Mouries, J, Carloni, S., Lizier, M., Romero-Gomez, M., Penna¹, G., Sannino⁴, A., **Rescigno, M.** Biomimetic superabsorbent hydrogel acts as a gut protective dynamic exoskeleton improving metabolic parameters and fostering A. muciniphila expansion. 2023, *Cell Reports Medicine*, Oct 17;4(10):101235. doi: 10.1016/j.xcrm.2023.101235.
215. Romero-Ibarguengoitia ME, Rodríguez-Torres JF, Garza-Silva A, Rivera-Cavazos A, Morales-Rodriguez DP, Hurtado-Cabrera M, Kalife-Assad R, Villarreal-Parra D, Loose-Esparza A,

- Gutiérrez-Arias JJ, Mata-Porras YG, Ojeda-Salazar DA, Sanz-Sánchez MA, González-Cantú A, Azzolini E, **Rescigno M**. Association of vaccine status, reinfections, and risk factors with Long COVID syndrome. *Sci Rep*. 2024 Feb 2;14(1):2817. doi: 10.1038/s41598-024-52925-4.PMID: 38307886
216. Bonifacio C, Savini G, Reca C, Garoli F, Levi R, Vatteroni G, Balzarini L, Allocca M, Furfaro F, Buono AD, Armuzzi A, Danese S, Matteoli M, **Rescigno M**, Fiorino G, Politi LS. The gut-brain axis: Correlation of choroid plexus volume and permeability with inflammatory biomarkers in Crohn's disease. *Neurobiol Dis*. 2024 Jan 23;192:106416. doi: 10.1016/j.nbd.2024.106416. Online ahead of print.PMID: 38272141
 217. Morosi L, Miotto M, Timo S, Carloni S, Bruno E, Meroni M, Menna E, Lodato S, **Rescigno M**, Martano G. MSIPixel: a fully automated pipeline for compound annotation and quantitation in mass spectrometry imaging experiments. *Brief Bioinform*. 2023 Nov 22;25(1):bbad463. doi: 10.1093/bib/bbad463.PMID: 38102070
 218. Boesch M, Lindhorst A, Feio-Azevedo R, Brescia P, Silvestri A, Lannoo M, Deleus E, Jaekers J, Topal H, Topal B, Ostyn T, Wallays M, Smets L, Van Melkebeke L, Härtlova A, Roskams T, Bedossa P, Verbeek J, Govaere O, Francque S, Sifrim A, Voet T, **Rescigno M**, Gericke M, Korf H, van der Merwe S. Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH. *J Hepatol*. 2023 Nov 15:S0168-8278(23)05271-6. doi: 10.1016/j.jhep.2023.10.039. Online ahead of print.PMID: 37977244
 219. Ferrari, V. Lo Cascio, A., Melacarne, A., Tanaskovic, N. Mozzarelli, A.M. Tiraboschi, L. Lizier, M., Salvi, M., Braga, D., Algieri, F., Penna, G., **Rescigno, M.**, Sensitizing cancer cells to immune checkpoint inhibitors by microbiota-mediated upregulation of HLA class I, 2023, *Cancer Cell* 2023 Oct 9;41(10):1717-1730.e4. doi: 10.1016/j.ccell.2023.08.014. Epub 2023 Sep 21.PMID: 37738976
 220. Chiaro J, Antignani G, Feola S, Feodoroff M, Martins B, Cojoc H, Russo S, Fusciello M, Hamdan F, Ferrari V, Ciampi D, Ilonen I, Räsänen J, Mäyränpää M, Partanen J, Koskela S, Honkanen J, Halonen J, Kuryk L, **Rescigno M**, Grönholm M, Branca RM, Lehtiö J, Cerullo V. Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors. *Nat Commun*. 2023 Nov 3;14(1):7056. doi: 10.1038/s41467-023-42668-7.
 221. Blanco-Míguez A, Carloni S, Cardenas C, Dioguardi CC, Lambroia L, Capretti G, Nappo G, Fugazza A, Capogreco A, Armanini F, Asnicar F, Dubois L, Golzato D, Manghi P, Pinto F, Scuderi C, Casari E, Montorsi M, Anderloni A, **Rescigno M**, Repici A, Zerbi A, Peano C, Tamburini S, Rusconi R, Segata N. Microbial composition associated with biliary stents in patients undergoing pancreatic resection for cancer. *NPJ Biofilms Microbiomes*. 2024 Mar 30;10(1):35. doi: 10.1038/s41522-024-00506-8.PMID: 38555334
 222. Labetoulle M, Baudouin C, Benitez Del Castillo JM, Rolando M, **Rescigno M**, Messmer EM, Aragona P. How gut microbiota may impact ocular surface homeostasis and related disorders. *Prog Retin Eye Res*. 2024 Mar 8;100:101250. doi: 10.1016/j.preteyeres.2024.101250. Online ahead of print.PMID: 38460758 Review.
 223. Romero-Ibarguengoitia ME, Rodríguez-Torres JF, Garza-Silva A, Rivera-Cavazos A, Morales-Rodríguez DP, Hurtado-Cabrera M, Kalife-Assad R, Villarreal-Parra D, Loose-Esparza A, Gutiérrez-Arias JJ, Mata-Porras YG, Ojeda-Salazar DA, Sanz-Sánchez MA, González-Cantú A, Azzolini E, **Rescigno M**. Association of vaccine status, reinfections, and risk factors with Long COVID syndrome. *Sci Rep*. 2024 Feb 2;14(1):2817. doi: 10.1038/s41598-024-52925-4.PMID: 38307886

224. Bonifacio C, Savini G, Reca C, Garoli F, Levi R, Vatteroni G, Balzarini L, Allocca M, Furfaro F, Dal Buono A, Armuzzi A, Danese S, Matteoli M, **Rescigno M**, Fiorino G, Politi LS. The gut-brain axis: Correlation of choroid plexus volume and permeability with inflammatory biomarkers in Crohn's disease. *Neurobiol Dis.* 2024 Mar;192:106416. doi: 10.1016/j.nbd.2024.106416. Epub 2024 Jan 23. PMID: 38272141 **Free article.**
225. Morosi L, Miotto M, Timo S, Carloni S, Bruno E, Meroni M, Menna E, Lodato S, **Rescigno M**, Martano G. MSIpixel: a fully automated pipeline for compound annotation and quantitation in mass spectrometry imaging experiments. *Brief Bioinform.* 2023 Nov 22;25(1):bbad463. doi: 10.1093/bib/bbad463. PMID: 38102070
226. Boesch M, Lindhorst A, Feio-Azevedo R, Brescia P, Silvestri A, Lannoo M, Deleus E, Jaekers J, Topal H, Topal B, Ostyn T, Wallays M, Smets L, Van Melkebeke L, Härtlova A, Roskams T, Bedossa P, Verbeek J, Govaere O, Francque S, Sifrim A, Voet T, **Rescigno M**, Gericke M, Korf H, van der Merwe S. Adipose tissue macrophage dysfunction is associated with a breach of vascular integrity in NASH. *J Hepatol.* 2024 Mar;80(3):397-408. doi: 10.1016/j.jhep.2023.10.039. Epub 2023 Nov 15. PMID: 37977244
227. **Rescigno M.** BCG-mediated viral protection goes biphasic. *Nat Immunol.* 2024 Jan;25(1):13-14. doi: 10.1038/s41590-023-01713-9. PMID: 38168959
228. Iacucci M, Santacroce G, Majumder S, Morael J, Zammarchi I, Maeda Y, Ryan D, Di Sabatino A, **Rescigno M**, Aburto MR, Cryan JF, Ghosh S. Opening the doors of precision medicine: novel tools to assess intestinal barrier in inflammatory bowel disease and colitis-associated neoplasia. *Gut.* 2024 Jun 8;gutjnl-2023-331579. doi: 10.1136/gutjnl-2023-331579. PMID: 38851294
229. Garza-Silva A, Rivera-Salinas D, Rivera-Cavazos A, Fernández-Chau IF, Cepeda-Medina AB, Morales-Rodríguez DP, Barco-Flores IA, Sanz-Sánchez MÁ, Acciardi C, Paez-Bo G, Teixeira MM, Azzolini E, Pozzi C, **Rescigno M**, Romero-Ibarguengoitia ME. Effectiveness of different booster vaccine combinations against SARS-CoV-2 during a six-month follow-up in Mexico and Argentina. *Front Immunol.* 2024 May 14;15:1403784. doi: 10.3389/fimmu.2024.1403784. PMID: 38807602
230. De Sanctis R, Tiberio P, Jacobs F, Gaudio M, Benvenuti C, Giordano L, Torrisi R, Zambelli A, Pozzi C, Penna G, Santoro A, **Rescigno M.** Optimizing abemaciclib-induced diarrhea management in patients with breast cancer: a pragmatic 2-group study using a postbiotic microbiota stabilizer. *Oncologist.* 2024 May 20;oyae101. doi: 10.1093/oncolo/oyae101. PMID: 38767987
231. Luzzi A, Briata IM, Di Napoli I, Giugliano S, Di Sabatino A, **Rescigno M**, Cena H. Prebiotics, probiotics, synbiotics and postbiotics to adolescents in metabolic syndrome. *Clin Nutr.* 2024 Jun;43(6):1433-1446. doi: 10.1016/j.clnu.2024.04.032. PMID: 38704983
232. Santos J, **Rescigno M.** Gut Barrier Leakiness: Time to Take It Seriously? *Gastroenterology.* 2024 Aug 16:S0016-5085(24)05352-6. doi: 10.1053/j.gastro.2024.08.011. PMID: 39154775

Milano 27th August, 2024

